Scientists have discovered a possible treatment to bone marrow cancer. Cincinnati Children's Hospital Medical Center have found a new way to target the treatment of pre-malignant disorders called Myelodysplastic syndromes, or MDS.

MDS is a group of pre-malignant disorders in bone marrow that inhibit the production of healthy blood cells and can lead to acute myeloid leukemia. Researchers found that this is being caused by the over-expression of a protein called TRAF6 in blood cells drives the onset of MDS.

Overexpression or excessive expression of a gene (as that caused by increasing the frequency of transcription. It is now suspected that, if not most, cancers arise from overexpression of key cellular regulatory genes.

The researchers added that they have a number of therapeutic approaches that can be tested and directed against TRAF6.

The researchers use laboratory mouse and human MDS/AML samples to identify a new substrate of TRAF6 called hnRNPA1. It is an RNA building protein. They discovered molecular interactions with Cdc42.

Cdc42 is a protein that regulates cells found in cancer. Their research could lead to a potential treatment to bone marrow cancer.

According to the UPI, researchers were also able to identify new molecular targets by conducting a global proteomic analysis of human leukemia cells. This has unveiled a new and critical immune-related functions for TRAF6.

The research team was led by cancer biologist Daniel Starczynowski, PhD. The authors published their data December 26, 2016.

According to the Science Daily, researchers were able to able to identify the new molecular targets by conducting a global Proteomic analysis of human leukemia cells. Allowing them to see entire complement of proteins regulated by TRAF6 in leukemia cells.

The researchers would further study on the therapeutic approaches that they have found. The discovery of the new method on how to cure bone marrow cancer is good news for cancer patients.